JP2023514570A5 - - Google Patents
Info
- Publication number
- JP2023514570A5 JP2023514570A5 JP2022548899A JP2022548899A JP2023514570A5 JP 2023514570 A5 JP2023514570 A5 JP 2023514570A5 JP 2022548899 A JP2022548899 A JP 2022548899A JP 2022548899 A JP2022548899 A JP 2022548899A JP 2023514570 A5 JP2023514570 A5 JP 2023514570A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- sirna
- composition according
- complement
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977012P | 2020-02-14 | 2020-02-14 | |
| US62/977,012 | 2020-02-14 | ||
| US202062980100P | 2020-02-21 | 2020-02-21 | |
| US62/980,100 | 2020-02-21 | ||
| US202063062321P | 2020-08-06 | 2020-08-06 | |
| US63/062,321 | 2020-08-06 | ||
| PCT/US2021/018071 WO2021163654A1 (en) | 2020-02-14 | 2021-02-13 | Rnas for complement inhibition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514570A JP2023514570A (ja) | 2023-04-06 |
| JP2023514570A5 true JP2023514570A5 (https=) | 2024-02-05 |
Family
ID=77292725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548899A Pending JP2023514570A (ja) | 2020-02-14 | 2021-02-13 | 補体阻害のためのｒｎａ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230095695A1 (https=) |
| EP (1) | EP4103716A4 (https=) |
| JP (1) | JP2023514570A (https=) |
| KR (1) | KR20220155301A (https=) |
| CN (1) | CN115335524A (https=) |
| AU (1) | AU2021221035A1 (https=) |
| CA (1) | CA3170158A1 (https=) |
| IL (1) | IL295517A (https=) |
| MX (1) | MX2022009870A (https=) |
| WO (1) | WO2021163654A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11510939B1 (en) | 2019-04-19 | 2022-11-29 | Apellis Pharmaceuticals, Inc. | RNAs for complement inhibition |
| WO2022226127A1 (en) * | 2021-04-20 | 2022-10-27 | Alexion Pharmaceuticals, Inc. | Compositions and methods for inhibiting complement component 3 expression |
| EP4398926A4 (en) * | 2021-09-09 | 2025-07-02 | Apellis Pharmaceuticals Inc | TREATMENT OF GEOGRAPHIC ATROPHY |
| WO2024092105A2 (en) | 2022-10-27 | 2024-05-02 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of complement component c3 (c3), pharmaceutical compositions thereof, and methods of use |
| CN121488036A (zh) * | 2023-07-21 | 2026-02-06 | 上海舶望制药有限公司 | 用于抑制补体成分3(c3)表达的组合物和方法 |
| WO2025026124A1 (zh) * | 2023-08-03 | 2025-02-06 | 苏州炫景生物科技有限公司 | C4b基因抑制剂组合物及其应用 |
| WO2025179182A2 (en) * | 2024-02-22 | 2025-08-28 | Apellis Pharmaceuticals, Inc. | C3 targeted inhibitory rna |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2670801A1 (en) * | 2005-11-30 | 2007-06-07 | Intradigm Corporation | Compositions and methods of using sirna to knockdown gene expression and to improve solid organ and cell transplantation |
| WO2007124452A2 (en) * | 2006-04-20 | 2007-11-01 | The Regents Of The University Of California | Methods for expressing multiple sirna and shrna from a single vector |
| IL288931B2 (en) * | 2013-03-14 | 2025-05-01 | Alnylam Pharmaceuticals Inc | Compositions comprising a complementary portion of C5 IRNA and methods of using them |
| RU2019113301A (ru) * | 2016-10-17 | 2020-11-17 | Апеллис Фармасьютикалс, Инк. | Комбинированная терапия для ингибирования с3 |
| SG11202002940QA (en) * | 2017-11-01 | 2020-04-29 | Alnylam Pharmaceuticals Inc | Complement component c3 irna compositions and methods of use thereof |
-
2021
- 2021-02-13 IL IL295517A patent/IL295517A/en unknown
- 2021-02-13 MX MX2022009870A patent/MX2022009870A/es unknown
- 2021-02-13 KR KR1020227031848A patent/KR20220155301A/ko active Pending
- 2021-02-13 US US17/798,339 patent/US20230095695A1/en active Pending
- 2021-02-13 JP JP2022548899A patent/JP2023514570A/ja active Pending
- 2021-02-13 WO PCT/US2021/018071 patent/WO2021163654A1/en not_active Ceased
- 2021-02-13 AU AU2021221035A patent/AU2021221035A1/en active Pending
- 2021-02-13 CA CA3170158A patent/CA3170158A1/en active Pending
- 2021-02-13 CN CN202180024287.XA patent/CN115335524A/zh active Pending
- 2021-02-13 EP EP21754090.5A patent/EP4103716A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023514570A5 (https=) | ||
| AU780517B2 (en) | Medicament for treatment of duchenne muscular dystrophy | |
| US6727355B2 (en) | Pharmaceutical composition for treatment of Duchenne muscular dystrophy | |
| US20200263179A1 (en) | Compositions and methods for inhibiting gene expression of lpa | |
| JP7258773B2 (ja) | α－１アンチトリプシン（ＡＡＴ）ＲＮＡｉ剤、ＡＡＴ ＲＮＡｉ剤を含む組成物、及び使用方法。 | |
| JP2023073358A (ja) | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 | |
| US20010056077A1 (en) | Pharmaceutical composition for treatment of duchenne muscular dystrophy | |
| JP2009537129A (ja) | エキソンスキッピングを誘発する為の手段及び方法 | |
| US20240084309A1 (en) | Compositions and methods for inhibiting plp1 expression | |
| JP7660515B2 (ja) | 病態及び疾患の治療用アンチセンスオリゴマー | |
| JP2026510791A (ja) | インヒビンサブユニットベータｅ（ｉｎｈｂｅ）遺伝子の発現を阻害するための組成物および方法 | |
| AU2023237229A1 (en) | Methods of treating glaucoma. | |
| EP4665852A1 (en) | Modified double stranded rna agents | |
| JP2024524974A (ja) | ナンセンス変異依存ｒｎａ分解機構に基づく病態及び疾患の処置のためのアンチセンスオリゴマー | |
| JP2024515240A5 (https=) | ||
| WO2025201416A1 (zh) | 靶向抑制素亚单位βE的核酸及其用途 | |
| WO2025103391A1 (zh) | 用于抑制lpa的基因表达的sirna，含其的组合物及其用途 | |
| CN113924364A (zh) | 治疗亨廷顿病的组合物和方法 | |
| US20250084420A1 (en) | Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22 | |
| JP2024507717A5 (https=) | ||
| CN101748122B (zh) | 抑制tm4sf4表达的干扰分子及其应用 | |
| US20240409938A1 (en) | Lipophilic sirna conjugates for the treatment of central nervous system diseases | |
| US20230183698A1 (en) | Prophylactic or therapeutic agent for at least one type of cancer selected from group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma and liver cancer, prophylactic or therapeutic agent for said cancer which is used in combination drug in combination with said agent, combination drug comprising said agents, and method for screening for prophylactic or therapeutic agent for cancer | |
| KR101888104B1 (ko) | MET 엑손 14 스키핑 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
| WO2025256564A9 (en) | iRNA COMPOSITION AND METHOD OF USING SAME |